ArticleBMC pharmacology & toxicology2026
Preservative-free latanoprost induces meibomian gland dysfunction through inflammatory and oxidative stress pathways.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to investigate the effects of preservative-free latanoprost on meibomian gland function in mice and its possible mechanism.
methodsDisproportionality analysis was conducted using the FAERS database to evaluate adverse reaction reports and epidemiological characteristics associated with preservative-free latanoprost. In mouse models, 0.005% preservative-free latanoprost or vehicle control was topically applied four times daily for 7, 14, or 28 days. Morphological changes of the meibomian gland in mice were detected by immunohistochemistry. Immunofluorescence staining, western blotting, and quantitative real-time PCR (qRT-PCR) were used to assess the expression of the prostaglandin F2α receptor (FP), inflammatory cells and mediators, oxidative stress-related markers, and signaling pathway–related factors in mouse meibomian gland tissues.
resultsReports of adverse reactions caused by preservative-free latanoprost increased annually in the FAERS database. Locally applied preservative-free latanoprost in mice led to an escalation of mucous secretion at the eyelid margin, accompanied by meibomian gland duct obstruction, lipid accumulation in glandular acini, an elevation in the expression levels of FP and Slco2a, and a reduction in the expression levels of PGDH within the meibomian glands. Other inflammatory markers, including CCL2, IL-1β, TNF-α, IL-6, and CXCL5, were significantly upregulated in the latanoprost-treated group, showing approximately 1.3–1.5-fold increases in CCL2, IL-1β, TNF-α, and CXCL5, and a more pronounced ~4-fold increase in IL-6 (p < 0.05). Consistently, oxidative stress-related proteins NOX4, 3-nitrotyrosine (3-NT), and 4-hydroxynonenal (4-HNE) were significantly increased (~1.3–1.5-fold, p < 0.05), whereas the antioxidant proteins superoxide dismutase 2 (SOD2) and Keap-1 were significantly altered, with SOD2 decreased to ~0.6-fold and Keap-1 increased to ~1.2-fold compared with controls (p < 0.05). Additionally, the Erk and NF-κB signaling pathways were significantly activated.
conclusion0.005% preservative-free latanoprost induces meibomian gland dysfunction in mice by promoting inflammatory responses and oxidative stress. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.